Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain scans reveal how gut talks to brain in obesity

NCT ID NCT05437653

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used MRI to examine how the brain and gut communicate after eating different types of drinks in people with obesity and healthy weight. Researchers gave participants a high-fat drink or a carbohydrate drink and scanned their brains and stomachs. The goal was to develop better imaging methods and understand why some people may be heavier than others.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nutritional drinks (high-fat emulsion and carbohydrate drink)
What this could lead to
If successful, this could help explain how the brain and gut interact to control appetite, potentially pointing toward new approaches for managing obesity.
What could go wrong
This is a small, early-stage imaging study with only 24 participants. It is designed to develop methods, not test a treatment, so direct benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Mar 2022

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-45, male and female (females will have the study days arranged during the early phase of the menstrual cycle). * Body mass index (BMI): normal weight participants ≥ 19 and ≤ 25 Kg/m2, and obese participants \> 30 Kg/m2 * Able to give voluntary written informed consent to participate in the study * Able to understand the requirements of the study * Apparently healthy: no medical conditions which might affect study measurements (judged by health questionnaire, and blood screening) Exclusion Criteria: * Any reported history of neurological or gastrointestinal disorders * Any reported history of surgery that could affect gastrointestinal function (e.g. colectomy, small bowel resection) * Abnormal screening procedures including depression and eat restriction * Laboratory results that are clinically significant, including diabetes, dyslipidemia, pancreatitis, or untreated hypertension. * Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury, assessed by standard MRI safety questionnaire. * Under medication (expect aspirin/paracetamol), antibiotic or prescribed probiotic treatment in the past 12 weeks. * Following a medically- or self-prescribed diet during the two weeks prior to the pre-study examination and until the end of the study. * Reported weight loss or gain ≥ 10 % of bodyweight during the six months period before the pre-study examination * Pregnancy or breastfeeding declared by candidate * Smoking * Left-handed assessed by handedness questionnaire. This is to control for brain's lateralisation effects (activation in one side of the brain) that may show variations between left and right handed participants. * Participation in another clinical or research study within the previous 3 months of the study * Cannot lie flat or exceeding the scanner bed weight limit of 250 kg. * Poor understanding of the spoken and/or written English language

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Nottingham

    Nottingham, NG7 2RD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.